TY - JOUR T1 -肺动脉高压从静脉注射环氧丙烷到selexipag的转变:警告JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02418 -2019欧元SP - 1902418 AU -谷,艾丽西亚盟——Soumagne AU - Guillien贤Thibaud盟——驱魔师,贾斯汀盟执行理事——皮里尔热医生说道尼古拉斯AU -皮卡德,弗朗索瓦盟——第一道,克利斯朵夫盟——Sitbon Olivier盟——Bouvaist Helene盟——Degano布鲁诺Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/02/20/13993003.02418 - 2019. -抽象N2 -环前列腺素类似物针对环前列腺素途径是用于治疗肺动脉高血压患者(PAH),并给出了通过静脉注射(IV),皮下(SC)或吸入途径[1]。在最严重的PAH[2]的治疗中，持续静脉滴注环氧丙烷已获得最强烈的推荐，这主要是因为在随机对照研究[3]中，它是唯一被证明能提高生存率的PAH特异性药物。由于与静脉给药相关的缺点，epoprostenol优先用于年轻、高危的[2]患者。对于在纽约心脏协会(NYHA)功能分级(FC) III/IV中存在严重血流动力学障碍的多环芳烃患者，epoprostenol可与内皮素受体拮抗剂(ERA)和磷酸二酯酶5型(PDE-5)抑制剂联合使用，以达到持续的临床和血流动力学疗效[4,5]。该手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以公认的形式在这里出版。当这些生产过程完成并且作者已经批准了结果证明之后，文章将转移到最新一期的在线ERJ。请打开或下载PDF阅读本文。利益冲突:Yanaka博士没有什么要披露的。Conflict of interest: Dr Guillien has nothing to disclose.Conflict of interest: Dr Soumagne has nothing to disclose.Conflict of interest: Dr Benet has nothing to disclose.Conflict of interest: Dr Piliero has nothing to disclose.Conflict of interest: Dr Picard has nothing to disclose.Conflict of interest: Dr Pison reports grants and personal fees from GlaxoSmithKline, personal fees from Novartis Pharma, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, outside the submitted work.Conflict of interest: Dr Sitbon reports personal fees from Arena Pharmaceuticals, personal fees and non-financial support from Actelion Pharmaceuticals, personal fees from Acceleron Pharmaceuticals, grants and personal fees from Bayer HealthCare, non-financial support from GlaxoSmithKline, personal fees from Gossamer Bio, grants and personal fees from Merck, outside the submitted work.Conflict of interest: Dr Bouvaist reports grants and non-financial support from GlaxoSmithKline, grants and non-financial support from Bayer HealthCare, personal fees and non-financial support from Actelion Pharmaceuticals, outside the submitted work.Conflict of interest: Dr Degano reports personal fees and non-financial support from Actelion Pharmaceuticals, non-financial support from Bayer HealthCare, grants, personal fees and non-financial support from Novartis Pharma, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Menarini, outside the submitted work. ER -